CSIMarket Company Name, Ticker, Customers, else..
 
T2 Biosystems Inc   (NASDAQ: TTOO)
 
Price: $0.0010 $0.00 0.000%
Day's High: $0.0010000000474974513 Week Perf: 66.67 %
Day's Low: $ 0.00 30 Day Perf: 100 %
Volume (M): 1,280 52 Wk High: $ 0.08
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 18
 Employees 60
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -43
 Cash Flow (TTM) (Millions $) -22
 Capital Exp. (TTM) (Millions $) 0

Business Description


T2 Biosystems Inc is a healthcare company that develops and commercializes innovative diagnostic products for the detection of challenging infectious diseases. Their core technology, called T2 Magnetic Resonance, enables rapid and accurate detection of pathogens and their related biomarkers from various clinical samples. This technology eliminates the need for traditional culture-based methods, which can be time-consuming. T2 Biosystems' products are designed to improve patient outcomes by providing faster and more accurate diagnoses, allowing for more effective treatment decisions.


   Company Address: 101 Hartwell Avenue Lexington 2421 MA
   Company Phone Number: 761-4646   Stock Exchange / Ticker: NASDAQ TTOO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CODX        1.64% 
INBS   -4%    
AXDX   -75.36%    
QDEL   -0.41%    
RJET   -7.29%    
• View Complete Report
   



Contract

T2 Biosystems Secures Commitment from Vizient Amid Revenue Challenges

Published Sun, Dec 29 2024 6:36 PM UTC

T2 Biosystems Extends Partnership with Vizient Despite Financial Instability LEXINGTON, Mass. In a move that underscores its commitment to addressing critical healthcare challenges, T2 Biosystems, Inc. (NASDAQ: TTOO), a pioneer in the rapid detection of sepsis-causing pathogens, has announced the extension of its multi-year capital equipment supplier agreement with Vizient...
Product Service News

T2 Biosystems Reaches Major Milestone with Global Shipment of 250,000 Sepsis Tests Amidst Financial Headwinds,

Published Sun, Dec 29 2024 11:59 AM UTC

T2 Biosystems Surpasses Key Milestone with 250,000 Sepsis Tests Shipped Globally Amid Financial Challenges In a significant achievement for T2 Biosystems Inc, the company has successfully shipped its 250,000th novel sepsis test globally, marking a crucial milestone in the adoption of its proprietary technology. This achievement reflects the growing global demand for T2 Biosy...
Product Service News

Global Expansion T2 Biosystems Bolsters European Presence with Key Instrument Sale,

Published Sat, Dec 28 2024 4:07 AM UTC

T2 Biosystems Strengthens European Market Presence with Strategic Instrument Sale T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has announced a significant step forward in its expansion into the European diagnostics market. The company recently completed the sale of four T2Dx Instruments to an established European...
Partnership

Innovations in Bio-Diagnostics and AI A Strategy for Combating Antimicrobial Resistance

Published Tue, Oct 8 2024 1:01 PM UTC

The ever-evolving landscape of antimicrobial resistance (AMR) presents an increasingly formidable challenge to public health worldwide. In response to this growing crisis, two cutting-edge biotechnology companies, T2 Biosystems, Inc. and Prxcision, Inc. have joined forces in a strategic co-marketing collaboration aimed at revolutionizing the field of diagnostics and antibiot...
Product Service News

T2 Biosystems Navigates Financial Turbulence with FDA Nod for Pediatric T2Candida Panel,

Published Mon, Sep 16 2024 1:00 PM UTC

T2 Biosystems Receives FDA Clearance to Market T2Candida Panel for Pediatric Patients Amid Financial Challenges T2 Biosystems Inc. a prominent player in the field of innovative diagnostic solutions, has achieved a significant milestone. The company announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market the T2Candida Panel for pedi...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.00
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.09
Working Capital Ratio 0.4
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -7.83 $
Revenues (TTM) 0.43 $
Cash Flow (TTM) -
Cash 0.12 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 127,950
Net Income per Employee (TTM) -715,900
Receivable Turnover Ratio (TTM) 4.85
Inventory Turnover Ratio (TTM) 5.15
Asset Turnover Ratio (TTM) 0.4

Profitability Ratios Current
Gross Margin (MRQ) -106.6 %
Operating Margin (MRQ) -511.89 %
Net Margin (MRQ) -509.67 %
Net Cash Flow Margin (MRQ) -108.97 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.